Bexil Corporation is a holding company operating businesses directly or through companies in which it has a majority or other substantial interest. It intends to acquire and/or develop one or more businesses. Bexil's preferred transaction is a management buyout. Particularly interested in a spinoff from a larger company, Bexil can provide the equity component of a leveraged buyout (LBO) financing. Based in New York, the company is evaluating opportunities to develop and acquire long-term acute care hospitals (LTACHs).
Revenue (Most Recent Fiscal Year) | $2.67M |
Net Income (Most Recent Fiscal Year) | -- |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | -- |
Quick Ratio (Most Recent Fiscal Quarter) | -- |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NYSEMKT |
Sector | Financial Services |
Industry | Asset Management |
Common Shares Outstanding | 0.61M |
Free Float | -- |
Market Capitalization | $25.77M |
Average Volume (Last 20 Days) | 17.60 |
Beta (Past 60 Months) | -0.21 |
Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |